date:May 07, 2014
Royal DSM, the Life Sciences and Materials Sciences company, today reported first quarter EBITDA from continuing operations of 272 million compared to 301 million in Q1 2013. This performance was delivered against significant adverse foreign exchange rates. As expected, Nutrition experienced in Q1 the continued impact of the market headwinds, which also affected Q4 2013. Materials Sciences was impacted by lower results in caprolactam.
Commenting on the results, Feike Sijbesma, CEO/Chairman of t